Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

November 30, 2007

Study Completion Date

March 31, 2009

Conditions
Diabetes MellitusDiabetic Nephropathy
Interventions
DRUG

Pirfenidone

Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses

Trial Locations (3)

19107

The Center for Diabetic Kidney Disease at Thomas Jefferson University, Philadelphia

20892

National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), Bethesda

55905

Mayo Clinic, Rochester

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Sharma, Kumar, M.D.

INDIV

NCT00063583 - Pirfenidone: A New Drug to Treat Kidney Disease in Patients With Diabetes | Biotech Hunter | Biotech Hunter